1,2,3-Triazole derivatives with anti-breast cancer potential

Abstract:

Breast cancer is one of the most prevalent malignant diseases and one of the main mortality causes among women across the world. Despite advances in chemotherapy, drug resistance remains major clinical concerns, creating an urgent need to explore novel anti-breast cancer drugs. 1,2,3-Triazole is a privileged moiety, and its derivatives could inhibit cancer cell proliferation, and induce the cell cycle arrest and apoptosis. Accordingly, 1,2,3-triazole derivatives possess profound activity against various cancers including breast cancer. This review summarizes the latest progresses related to the anti-breast cancer potential of 1,2,3-triazole derivatives, covering articles published from January 2017 to December 2021. The mechanisms of action and structure-activity relationships (SARs) are also discussed for further rational design of more effective candidates.

Copper coordination compounds with (5Z,5Z')-2,2'-(alkane-α,ω-diyldiselenyl)-bis-5-(2-pyridylmethylene)-3,5-dihydro-4H-imidazol-4-ones. Comparison with sulfur analogue

A series of new organic ligands (5Z,5Z')-2,2'-(alkane-α,ω-diyldiselenyl)-bis-5-(2-pyridylmethylene)-3,5-dihydro-4H-imidazol-4-ones (L) consisting of two 5-(2-pyridylmethylene)-3,5-dihydro-4H-imidazol-4-one units linked with polymethylene chains of various lengths (n = 2-10, where n is the number of CH₂ units) have been synthesized. The reactions of these ligands with CuCl₂·2H₂O and CuClO₄·6H₂O gave Cu²⁺ or Cu¹⁺ containing mono- and binuclear complexes with Cu₂LCl _x (x = 2-4) or CuL(ClO₄) _y (y = 1, 2) composition. It was shown that the agents reducing Cu²⁺ to Cu¹⁺ in the course of complex formation can be both a ligand and an organic solvent in which the reaction is carried out. This fundamentally distinguishes the selenium-containing ligands L from their previously described sulfur analogs, which by themselves are not capable of reducing Cu²⁺ during complexation under the same conditions. A higher cytotoxicity and reasonable selectivity to cancer cell lines for synthesized complexes of selenium-containing ligands was shown; unlike sulfur analogs, ligands L themselves demonstrate a high cytotoxicity, comparable in some cases to the toxicity of copper-containing complexes.

Melnikov M, Zyk NV, Skvortsov DA, Lopatukhina EV, Vaneev AN, Gorelkin PV, Erofeev AS, Majouga AG, Beloglazkina EK. New Fe–Cu bimetallic coordination compounds based on ω-ferrocene carboxylic acids and 2-thioimidazol-4-ones: structural, mechanistic and biological studies

Synthesis, characterization and in vitro cytotoxic investigation of a series of new ferrocene-containing derivatives based on ω-ferrocene carboxylic acids and 2-alkylthioimidazolin-4-ones and their copper complexes have been reported.

Three types of copper derivatives formed by CuCl2·2H2O interaction with (Z)-3-aryl-2-(methylthio)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazol-4-ones

The reactions of (Z)-3-aryl-2-(methylthio)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazol-4-ones (3) with CuCl2·2H2O in the presence of a reducing solvent (alcohol or dimethylformamide (DMF)) produce three types of Cu-containing compounds: two Cu complexes with a composition of CuII(3)Cl2 (4) and CuI(3)Cl (5) as well as a salt (3 + H)+CuICl2- (6) in a 4 : 5 : 6 ratio depending on the substituent at the N(3) nitrogen atom of the ligand moiety. In non-reducing solvents (dimethyl sulfoxide (DMSO) and CHCl3/acetone), only complexes 4 were formed, All three Cu derivatives (4, 5, and 6) were characterized by single-crystal X-ray diffraction, UV/vis spectroscopy, and electrochemistry data. Convenient electrochemical and UV-vis spectral criteria were recorded, which made it possible to distinguish between the different Cu-containing compounds. Based on the electron spectroscopy and electron paramagnetic resonance (EPR) data, a possible scheme for the formation of compounds 4-6 was proposed, including the initial coordination of copper(ii) chloride with an organic ligand, the subsequent reduction of the resulting complex 4 by DMF with the formation of salt 6, and the further transition of salt 6 into the complex 5.

Ferrocene-containing hybrids as potential anticancer agents: Current developments, mechanisms of action and structure-activity relationships

Cancer is one of the most fatal threatens to human health throughout the world. The major challenges in the control and eradication of cancers are the continuous emergency of drug-resistant cancer and the low specificity of anticancer agents, creating an urgent need to develop novel anticancer agents. Organometallic compounds especially ferrocene derivatives possess remarkable structural and mechanistic diversity, inherent stability towards air, heat and light, low toxicity, low cost, reversible redox, ligand exchange, and catalytic properties, making them promising drug candidates for cancer therapy. Ferrocifen, a ferrocene-phenol hybrid, has demonstrated promising anticancer properties on drug-resistant cancers. Currently, Ferrocifen is in pre-clinical trial against cancers. Obviously, ferrocene moiety is a useful template for the development of novel anticancer agents. This review will provide an overview of ferrocene-containing hybrids with potential application in the treatment of cancers covering articles published between 2010 and 2020. The mechanisms of action, the critical aspects of design and structure-activity relationships are also discussed.